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As core skeletons of lamellarins: 5,6-Dihydropyrrolo[2,1-a]isoquinolines are one of the important alkaloids that exhibit signiﬁcant
biological activities, in this study, an eﬃcient synthetic route was described for two novel compounds, 5,6-dihydropyrrolo[2,1-
a]isoquinolines I and II. Compound I was synthesized from isovanillin with 28.3% overall yield by a six-step reaction while II
from 2-(3, 4-dimethoxyphenyl) ethanamine was with 61.6% overall yield by a three-step reaction. And the structures of these two
compounds were conﬁrmed by means of IR spectrum, 1H NMR, 13C NMR, MS, HRMS, and melting point measurements.
1.Introduction
Lamellarins are a group of hexacyclic marine alkaloids
that were initially isolated from a prosobranch mollusk by
Faulkner and coworkers in 1985 [1]. Since then, over 70
compounds belonging to this group have been isolated and
identiﬁed [2].
Some of these lamellarins and related compounds exhib-
it interesting biological activities in multidrug resistance
(MDR) and their corresponding parental cell lines [3]. As
well known [4], Lamellarin D (LMD) exhibits a signiﬁcant
cytotoxicity against a large panel of cancer cell lines and
is a potential non-CPT (camptothecin) topoisomerase 1
poison [5, 6]. LMD aﬀects cell cycle and acts on cancer cell
mitochondria to induce apoptosia [7].
Due to the fascinating novel structures and biological
activities, more and more researchers have devoted into
the synthetic studies of lamellarins [8] and related 3,4-
diarylpyrrolo derivatives. As one of the important alka-
loids, 5,6-Dihydropyrrolo[2,1-a]isoquinolines exhibits pro-
nounced biological activities. The biological activity of 5,6-
dihydropyrrolo[2,1-a]isoquinolines I and II was evaluated
by their eﬀects on the proliferation of MDA-MB-231 (breast
cancer cell line) by MTT assay. Our results showed that
compound I could signiﬁcantly inhibit the proliferation of
MDA-MB-231 at the concentration of 40μg/mL, in contrast,
compound II could enhance the proliferation of the MDA-
MB-231 at the same concentration. In addition, they are also
scaﬀolds for synthesis of lamellarin analogues [9].
Increasingly elegant synthetic routes have been devel-
oped. An eﬃcient synthetic route for two compounds,
8-benzyloxy-9-methoxy-2-(2,4,5-trimethoxyphenyl)-5,6-di-
hydropyrrolo[2,1-a]isoquinoline (I) and 8,9-dimethoxy-2-
(2,4,5-trimethoxyphenyl)-5,6-dihydro[2,1-a]isoquinoline
(II), is mainly introduced in this study. The synthetic
procedure is very valuable because it employs 5,6-dihydro-
pyrrolo[2,1-a]isoquinolines as starting materials and repre-
sents an easy and direct approach to a wide variety of 3,4-di-
hydroisoquinolines. The synthetic strategy is outlined in
Scheme 1.
Isovanillin was protected with benzyl chloride to get
3-benzyloxy-4-methoxy-benzaldehyde (1) with 84.4% yield
[10], which was condensed with nitromethane giving
2-benzyloxy-1-methoxy-4-(2-nitrovinyl)-benzene (2) with
80.5% yield [11]. Compound 2 was then reduced with
LiAlH4 to get 2-(3-benzyloxy-4-methoxyphenyl)-vinylam-
ine (3) with 84.9% yield [12]. Treatment of 3a∼b with
acetylchloride (n(3a∼b):n(CH3COCl):n(Et3N)=1:1.8: 4.0)
aﬀorded acetamide (4a∼b) with 81.9% and 90.7% yield,
respectively, followed by cyclization with phosphorous oxy-
chloride to get 3,4-dihydroisoquinoline (5a∼b) with 80.0%
and 83.6% yield (n(4a):n(POCl 3)= 1:8). A solution of2 Evidence-Based Complementary and Alternative Medicine
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Scheme1:Reagentsandconditions:(i)BnCl,K2CO3,E tOH,r eﬂux,5h,94%;(ii)CH 3NO2,NH 4OAc,AcOH,reﬂux,4h,80.5%;(iii)LiAlH4,
THF, reﬂux, 6h, 84.9%; (iv) CH3COCl, Et3N, CH2Cl2,0 ◦C, 2h, 4a: 81.9%, 4b: 90.7%; (v) POCl3,C H 2Cl2, reﬂux, 3h, 5a: 80.0%, 5b: 83.6%;
(vi) 2-halogen-1-(2,4,5-trimethoxyphenyl)ethanone, CH3CN, K2CO3, reﬂux, 20h, I: 74.7%, II: 72.6%.
5a∼b, 2-bromo-1-(2,4,5-trimethoxy-phenyl)-ethanone and
anhydrous K2CO3 in anhydrous acetonitrile was reﬂuxed
for 15h. After a series of treatment, 5,6-dihydropyrrolo[2,1-
a]isoquinoline I and II were obtained with 28.3% and 61.6%
total yield, respectively.
2.MaterialandMethods
2.1. Analysis Means of Compounds. Melting points (uncor-
rected)weredeterminedbyaGongyiX-4apparatus.Infrared
spectra(IR) were determined by Nicolet 550 spectrometer.
NMR spectra were recorded by Bruker DRX500 or Bruker
DRX400 spectrometer.Alldatawerecalibratedat δ 0.00ppm
for 1Hs p e c t r aa n d13C spectra from the original spectra
(TMS). Low resolution mass spectra (LRMS) were recorded
with an HP 6890/5973 GC-MS mass spectrometer. High
resolution mass (HRMS) for unreported compounds were
recorded with a Micromass GTC Gas Chromatography/TOF
Mass spectrometer. All solvent were redistilled prior to use,
unless otherwise stated, all other commercially available
chemicals were used without further puriﬁcation.
2.2. Chemical Synthesis
2.2.1. 3-(benzyloxy)-4-methoxybenzaldehyde (1). Am i x t u r e
of isovanillin (10.0g, 66mmol), benzyl chloride (16mL,
139mmol),andanhydrousK2CO3 (6.5g,47mmol)inEtOH
(150mL) was reﬂuxed for 5h. After being stirred, the
reaction mixture was concentrated to dry and redissolved
in 70mL CH2Cl2, and then 5% aqueous NaOH (3 ×
100mL) was added. The organic layer was washed with brine
(2 × 50mL) and H2O( 2× 50mL), dried with anhydrous
Na2SO4, and evaporated to dryness. Needles were obtained
after crystallization from MeOH/CH2Cl2 corresponding to
3-(benzyloxy)-4-methoxybenzaldehyde (15.0g, 94%): m.p.
61∼62◦C(lit.13 m.p.61∼62◦C); 1HNMR(400MHz,CDCl3)
δ 9.82 (s, 1H), 7.45∼7.47 (m, 4H), 7.38 (t, 2H, J = 7.34Hz),
7.32 (t, 1H, J = 7.34Hz), 6.99 (d, 1H, J = 8.24), 5.19 (s, 2H),
3.96 (s, 3H); MS (EI, 70ev) m/z: 242(M+), 92, 91, 79, 77, 65,
63, 51.
2.2.2. (E)-2-(benzyloxy)-1-methoxy-4-(2-nitrovinyl)benzene (2).
As o l u t i o no fc o m p o u n d1 (10.0g, 41mmol), nitromethane
(7mL, 129mmol) and NH4OAc (8.0g, 104mmol) in AcOH
(125mL) was reﬂuxed for 4h. After cooling, the mixture
was diluted with H2O (100mL) and extracted with CH2Cl2
(3 × 100mL). The organic solution was washed with brine
(2 × 100mL) and H2O( 2× 100mL), dried with anhydrous
Na2SO4, and evaporated to dryness. Yellow needles were
obtained from EtOH corresponding to (E)-2-(benzyloxy)-
1-methoxy-4-(2-nitrovinyl)benzene (2) (9.6g, 80.5%): m.p.
127∼128◦C (lit.14 m.p. 125∼126◦C)1H NMR (400MHz,
CDCl3) δ 7.91 (d, J = 13.6Hz, 1H), 7.33∼7.46 (m, 6H) 7.18
(dd, J = 2.0, 8.36Hz, 1H), 7.03 (d, J = 2.0Hz, 1H), 6.93 (d,
J = 8.36Hz, 1H), 5.17 (s, 2H), 3.95 (s, 3H); MS (EI, 70ev)
m/z: 285 (M+), 92, 91, 77, 65, 63, 51.
2.2.3. 2-(3-(benzyloxy)-4-methoxyphenyl)ethanamine (3). A
solutionofcompound2(4.0g,14.0mmol)in14mLofanhy-
drous THF was added dropwise to a well-stirred suspension
of LiAlH4 (2.0g, 52.8mmol) in 50mL of anhydrous THF
and was reﬂuxed for 6h. After the solution was cooled, the
excess reagent was destroyed by dropwise addition of EtOAc
and 15% aqueous NaOH. After partial evaporation of the
ﬁltered portion, the aqueous solution was extracted with
CH2Cl2 (3 × 30mL), and the organic solution was washed
with brine (2 × 20mL) and H2O( 2× 20mL), dried with
anhydrous Na2SO4, and evaporated to dryness, and then
2-(3-(benzyloxy)-4-methoxyphenyl)ethanamine (3) (3.0g,
84.9%) was obtained as an oil. 1H NMR (400MHz, CDCl3)Evidence-Based Complementary and Alternative Medicine 3
δ 6.73∼7.44 (m, 8H), 5.12 (s, 2H), 3.85 (s, 3H), 2.85 (t,
J = 6.7Hz, 2H), 2.62 (t, J = 6.7Hz, 2H), 2.20 (br s, 2H);
MS (EI, 70ev) m/z: 257 (M+), 229, 228, 167, 137, 92, 91, 65.
2.2.4. N-(3-(benzyloxy)-4-methoxyphenethy)acetamide (4a).
A solution of 0.4mL of acetyl chloride (5.6mmol) in
5mL anhydrous CH2Cl2 was added dropwise at 0◦Ct o
as o l u t i o no fc o m p o u n d3 (1.0g, 3.88mmol) and Et3N
(1.7mL, 12.26mmol) in 20mL anhydrous CH2Cl2,w i t h
stirring at 0◦C for 2h. After the mixture was stirred, 2.5%
aqueousHClwasaddedandtheorganicsolutionwaswashed
withbrine(2×10mL)andH2O(2×10mL),driedwithanhy-
drous Na2SO4, evaporated to dryness, and pale-yellow solid
was obtained. Crude product was crystallized with EtOAc
to aﬀord N-(3-benzyloxy-4-methoxyphenylethyl)acetamide
(0.94g, 81.9%) as white crystals. m.p. 106∼108◦C (lit.15 m.p.
122∼123◦C); 1H NMR (400MHz, CDCl3) δ 7.44 (d, J =
7.2Hz, 2H), 7.36 (t, J = 7.2Hz, 2H), 7.30 (d, J = 7.2Hz,
1H), 6.84 (d, J = 8.8Hz, 1H), 6.74 (d, J = 6.8Hz, 2H), 5.14
(s, 2H), 3.87 (s, 3H), 3.43 (q, J = 6.8, 12.8Hz, 2H), 2.70 (t,
J = 6.8Hz, 2H), 1.88 (s, 3H).
2.2.5. 6-(benzyloxy)-7-methoxy-1-methyl-3,4-dihydroiso-quin-
oline(5a). Asolutionof0.9mLofPOCl3 (9.8mmol)in6mL
anhydrous CH2Cl2 was added dropwise at 40◦Ct oas o l u t i o n
of compound 4a (0.4g, 1.06mmol) in 10mL anhydrous
CH2Cl2, with stirring at 40◦C for 3h, then was poured
into ice-water mixture, 2.5% aqueous NaOH was added to
make pH about 12, the aqueous solution was extracted with
CH2Cl2 (3 × 20mL), and the organic solution was washed
withbrine(2×10mL)andH2O(2×10mL),driedwithanhy-
drousNa2SO4,evaporatedtodrynessandsolidwasobtained.
The crude product was puriﬁed with a silica gel column
(Petroleum:EtOAc(v/v)= 3:1, 200∼300 H) to aﬀord 6-
(benzyloxy)-7-methoxy-1-methyl-3,4-dihydroisoquinoline
(5a) (0.24g, 80%) as brick red crystals. m.p. 95∼96◦C; 1H
NMR (500MHz, CDCl3) δ 7.30∼7.44 (m, 5H), 7.01 (s, 1H),
6.7 (s, 1H), 5.17 (s, 2H), 3.90 (s, 3H), 3.61 (t, J = 7.2Hz,
2H), 2.57 (m, J = 1.3, 7.5Hz, 2H), 2.35 (t, J = 1.3Hz, 3H).
2.2.6. 8-benzyloxy-9-methoxy-2-(2,4,5-trimethoxyphenyl)-5,
6-dihydropyrrolo[2,1-a]isoquinoline (I). To a solution of
0.52g compound 5a (1.85mmol) in 15mL anhydrous
CH3CN was added 0.45g 2-bromo-1-(2,4,5-trimethoxy-
phenyl)-ethanone (1.85mmol). The reaction mixture was
stirred at 85◦C for 10h, then 0.38g anhydrous K2CO3
(2.75mmol) was added and continued to stir for another
10h. After that the mixture was poured into 15mL brine
and extracted with CH2Cl2 (3 × 15mL), the combined
organic layers were dried with anhydrous Na2SO4,
evaporated to dry, and brown oil was obtained. The crude
product was puriﬁed with a silicagelcolumn (Petroleum
:EtOAc(v/v) = 2:1, 200∼300 H) to aﬀord 8-benzyl-
9-methoxy-2-(2,4,5-trimethoxyphenyl)-5,6-dihydropyrrolo
[2,1-a]isoquinoline (I) (0.65g, 74.7%) as oﬀwhite sheet
solid. m.p. 128◦C; IR (KBr) ν: 2993, 2934, 2830, 1614, 1568,
1529, 1508, 1453,1427, 1365, 1336, 1274, 1166, 1130, 1035,
848, 810, 784, 738, 695cm−1; 1H NMR (500MHz, CDCl3)
δ 7.29–7.46 (m, 5H), 7.12 (d, J = 1.6Hz, 1H), 7.11 (s, 1H),
7.10 (s, 1H), 6.73 (s, 1H), 6.69 (d, J = 1.6Hz, 1H), 6.60 (s,
1H), 5.14 (s, 2H), 4.05 (t, J = 6.6Hz, 2H), 3.94 (s, 3H), 3.91
( s ,3 H ) ,3 . 9 1( s ,3 H ) ,3 . 8 8( s ,3 H ) ,2 . 9 5( t ,J = 6.6Hz, 2H);
13C NMR (500MHz, CDCl3) δ: 29.61, 44.91, 56.96, 56.97,
57.14, 57.43, 72.14, 99.34, 102.13, 107.32, 112.83, 115.18,
117.55, 120.83, 121.02, 123.60, 123.78, 128.03, 128.03,
128.50, 129.21, 129.21, 130.31, 137.98, 144.06, 147.25,
148.13, 149.82, 151.07; MS (LC-MS) m/z: 472 (M+1)+, 367,
318, 273; HRMS (ESI-Q-TOF) calcd for C29H29NO5 [M+1]+
472.4856, found 472.4819.
2.2.7. N-(3,4-dimethoxyphenethyl)acetamide (4b). As o l u -
tion of 7.6mL of acetyl chloride (0.11mol) in 10mL
anhydrous CH2Cl2 was added dropwise at 0◦Ct oas o l u t i o n
of compound 3b (10mL, 0.059mol) and Et3N (32.8mL,
0.23mol) in 25mL anhydrous CH2Cl2, with stirring at 0◦C
for 2h. After the mixture was stirred, 2.5% aqueous HCl was
added and the organic solution was washed with brine (2 ×
30mL) and H2O( 2×20mL), dried with anhydrous Na2SO4,
evaporated to dryness, and yellow solid was obtained.
Crude product was crystallized with EtOAc to aﬀord N-
(3,4-dimethoxyphenethyl) acetamide (4b) (11.8g, 90.7%) as
yellow crystals. m.p. 85∼86◦C (lit.16 m.p. 94◦C); IR (KBr) ν:
1642.54cm−1 (–C=O), 3301.49cm−1 (–NH–).
2.2.8. 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (5b).
A solution of 9.8mL of POCl3 (0.1mol) in 40mL anhy-
drous CH2Cl2 was added dropwise at 40◦Ct oas o l u t i o n
of compound 4b (3.0g, 13.4mmol) in 30mL anhydrous
CH2Cl2, with stirring at 40◦C for 3h, then was poured
into ice-water mixture; 2.5% aqueous NaOH was added
to make pH about 12, the aqueous solution was extracted
with CH2Cl2 (3 × 60mL), and the organic solution was
washed with brine (2 × 50mL) and H2O( 2× 50mL), dried
with anhydrous Na2SO4, evaporated to dryness, and solid
was obtained. The crude product was puriﬁed with a sil-
ica gel column (Petroleum:EtOAc(v/v)= 1:1, 200∼300H)
to aﬀord 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline
(5b) (2.3g, 83.6%) as brick red crystals. m.p. 98∼99◦C (lit.17
m.p. 85∼96◦C)1H NMR (500MHz, CDCl3) δ 6.99 (s, 1H),
6.89 (s, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.63 (m, J = 1.4,
7.5Hz, 2H), 2.63 (t, J = 7.5Hz, 2H), 2.36 (t, J = 1.4Hz,
3H).
2.2.9. 8,9-dimethoxy-2-(2,4,5-trimethoxyphenyl)-5,6-dihydro
[2,1-a]isoquinoline (II). T oas o l u t i o no f1 . 5gc o m p o u n d5 b
(7.32mmol) in 20mL anhydrous CH3CN was added 1.78g
2-bromo-1-(2,4,5-trimethoxy-phenyl)-ethanone (7.34mmol).
The reaction mixture was stirred at 85◦C for 10h, then
1.52g anhydrous K2CO3 (11.0mmol) was added and con-
tinued to stir for another 10h. After that the mixture
was poured into 30mL brine and extracted with CH2Cl2
(3 × 30mL), the combined organic layers were dried with
anhydrous Na2SO4,e v a p o r a t e dt od r y n e s s ,a n db r o w no i l
was obtained. The crude product was puriﬁed with a
silica gel column (Petroleum:EtOAc(v/v)= 2:1, 200∼300
H)toaﬀord8,9-dimethoxy-2-(2,4,5-trimethoxyphenyl)-5,6-
dihydro[2,1-a]isoquinoline (II) (0.65g, 72.6%) as gray solid.
m.p. 137∼138◦C; IR (KBr) ν: 2993, 2934, 2836, 1608,4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: 1H NMR spectrum of the I. Inserted ﬁgure is the magniﬁcation of the part of 7.00–7.50 of chemical shift.
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Figure 2: 13C NMR spectrum of the I. Inserted ﬁgure is the magniﬁcation of the part of 120.00–135.00 of chemical shift.
1560, 1530, 1508, 1484, 1397, 1272, 1212, 1126, 1036, 808,
776cm−1; 1H NMR (500MHz, CDCl3) δ:3 . 0 1( t ,J =
6.6Hz, 2H), 3.87 (s, 3H), 3.88 (s, 3H), 3.91 (s, 3H), 3.92 (s,
3H), 3.95 (s, 3H), 4.07 (t, J = 6.6Hz, 2H), 6.60 (s, 1H),
6.69 (d, J = 1.7Hz, 1H), 6.70 (s, 1H), 7.08 (s, 1H), 7.12
(s, 1H), 7.13 (d, J = 1.7Hz, 1H); 13C NMR (500MHz,
CDCl3) δ: 29.07, 44.28, 56.08, 56.15, 56.30, 56.49, 56.78,
98.68, 106.08, 101.36, 111.51, 112.19, 116.90, 120.12, 120.36,
122.43, 122.93, 129.70, 143.40, 147.38, 147.47, 148.38,
150.42; DEPT 135 (500MHz, CDCl3) δ: two –CH2 (29.06,
44.28), ﬁve –CH3 (56.07, 56.14, 56.29,56.48,56.76), six –CH
(98.62, 101.34, 106.05, 111.47, 112.15, 120.11); MS (LC-MS)
m/z: 396 (M+1)+, 371, 276; HRMS (ESI-Q-TOF) calcd for
C23H25NO5 [M+1]+ 396.4852, found 396.4884.
3. Results
The target compounds I and II had been synthesized by our
route and their structures were determined by interpretationEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: 1H NMR spectrum of the II. Inserted ﬁgure is the magniﬁcation of the part of 7.00–7.20 of chemical shift.
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Figure 4: 13C NMR spectrum of the II. Inserted ﬁgure is the magniﬁcation of the part of 110.00–130.00 of chemical shift.
of spectral data. The 1HN M Ra n d13C NMR spectra of them
were assigned as indicated in Figures 1, 2, 3,a n d4.
An initial 1H-NMR spectrum of I (in CDCl3) revealed
four –OMe–H signals at 3.94 (s, 3H), 3.91 (s, 3H), 3.91 (s,
3H),3.88(s,3H).Thesepeaksarethefeaturedsignalsofthe–
OMe–. 2.95 and 4.05 doublets (J = 6.6Hz) indicate –CH2N–
and –CH2– moieties connected with it in the isoquinoline
ring. It can be seen that the distinguishing feature of Ar–
CH2O 5.14 (s, 2H) is shown in Figure 1. There are several
groups of signals in the aromatic region; they are 7.12 (d,
J = 1.6Hz, 1H), 7.11 (s, 1H), 7.10 (s, 1H), 6.73 (s, 1H), 6.69
(d, J = 1.6Hz, 1H), and 6.60 (s, 1H), respectively. Among
them, 7.12 (d, J = 1.6Hz, 1H) and 6.69 (d, J = 1.6Hz, 1H)
are the signals in the pyrrole ring; this can be estimated from
the peak type. Since Ar–H in the Ar–CH2O are inﬂuenced by
other protons more slightly, they will overlap together and
show the multiplet in the spectra. So 7.29–7.46 (m, 5H) is
the signal of Ar–H in the Ar–CH2O. A molecular formula6 Evidence-Based Complementary and Alternative Medicine
of C29H29NO5,r e s u l t e df r o mH R - M Sd a t ao fI. The 13C
NMR spectrum of I displayed twenty-seven signals, which
represented all twenty-nine C-atoms, eighteen of which were
assignable to three aromatic-C moieties and accounted for
sixteen spectral signals. Of the remaining eleven signals, four
were from OMe (56.96, 56.97, 57.14, 57.43ppm), and seven
were from isoquinoline and pyrrole ring C-atoms.
NMR data of II (see Figures 3 and 4) indicated a
C23H25 framework, which HR-MS analysis expanded to a
molecular formula of C23H25NO5. The simplest assumed
relationship between the two isoquinoline, I as an BnO-
substitutedII,wasreinforcedbycharacterizationoftheNMR
data, which exhibited many similar signals. Speciﬁcally, too
many shifts of H and C resonances are very similar to
each other which proved the basic framework between I
and II. The NMR signals which distinguished I from II
were those of three aromatic protons appropriate for Ar–H
(7.29–7.46ppm, m, 5H) and –CH2–i nt h eA r – C H 2O. The
remaining distinguishing feature was the number of –OMe–
signal in 13C NMR at 56-57ppm.
4. Discussions
I and II from 1-methyl-3,4-dihydroisoquinoline and 2,4,5-
trimethoxy-α-halogen-acetophenone were obtained with
high yields under mild conditions for the ﬁrst time. This
novel method, as the key reaction step, provides a gen-
eral and highly eﬃcient method for the preparation of
5,6-dihydropyrrolo[2,1-a]isoquinolines. We envisaged that
the 5,6-dihydropyrrolo[2,1-a]isoquinolines could be con-
structed by the formation of quaternary ammonium salt,
and subsequent lactonization in the presence of anhy-
drous K2CO3. The negative carbon ion of 1-methyl-3,4-
dihydroisoquinoline is also active in the Knorr reaction.
Both 2,4,5-trimethoxy-α-bromoacetophenone and 2,4,5-
trimethoxy-α-chloracetophenone were employed. We found
that the yield of the former is about 5% higher than the later.
Therefore, 2,4,5-trimethoxy-α-bromoacetophenone is used
in the synthesis of I and II.
5. Conclusion
Based on the facile synthetic route depicted in Scheme 1,
two novel scaﬀolds for synthesis of lamellarin analogues
8-benzyloxy-9-methoxy-2-(2,4,5-trimethoxyphenyl)-5,6-
dihydropyrrolo[2,1-a] isoquinoline (I) and 8,9-dimethoxy-
2-(2,4,5-trimethoxyphenyl)-5,6-dihydro[2,1-a]isoquinoline
(II) were obtained under mild condition. These two
compounds are characterized by 1HN M R ,13C NMR, IR
spectrum, and melting points. The products are stable and
may be expected to exhibit biological activities to some
extend.
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